Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

  • End date
    Dec 23, 2024
  • participants needed
  • sponsor
    Yonsei University
Updated on 23 September 2021
antiplatelet agents
vitamin k antagonist
anticoagulant therapy
vitamin k
anticoagulation therapy


Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown their excellent safety and efficacy, and thus are widely accepted in clinical practice. Meanwhile, after percutaneous coronary intervention (PCI) using the drug-eluting stents due to coronary artery disease, the administration of one or more antiplatelets is essential to prevent the recurrence of stent thrombosis and myocardial infarction. Combined administration of anticoagulants and antiplatelets significantly lowers the incidence of ischemic events such as stroke and myocardial infarction, however, it also significantly increases the likelihood of bleeding leading to hospitalization, and or even death, thereby significantly affecting the clinical course of the AF patients who underwent PCI. Nevertheless, due to the very high mortality rate of stent thrombosis, the current standard of care guidelines recommend triple therapy with anticoagulants and double antiplatelet therapy (DAPT) in patients with atrial fibrillation for 1 month after coronary intervention, followed by co-administration of NOAC with single antiplatelet agent for 1 year. However, little is known after the optimal therapeutic strategy after 1 year. The purpose of this study is to compare the clinical results of single anticoagulant and clopidogrel combination therapy for maintenance therapy after 1 year in patients with atrial fibrillation.


Atrial fibrillation(AF) patients who had undergone PCI with DES implantation at 12-18 months ago will be enrolled in this study. Decision for the antiplatelet agent discontinuation would be determined by randomization. Apixaban would be prescribed to reduced the risk stroke or systemic embolism evoked by AF, and the administration of Warfarin, a vitamin-K dependent anticoagulant, would also be allowed according to attending physician's decision. The following criteria should be followed for the reduction of dosages according to the patient's renal function and other systemic conditions. Warfarin is administered to patients with creatinine clearance of 15 ml / min or dialysis. The drugs used in this study correspond to the international treatment guidelines after coronary intervention in patients with atrial fibrillation.NOAC and antiplatelet agents would be prescribed upon an outpatient visit. Clinical outcome would be followed for 2 years after study enrollment and randomization.


  • Baseline Serum AST/ALT level
  • Creatinine clearance (mL/min)
  • Concurrent administration of CYP3A4 agents: Ketoconazole, Itraconazole, Iopinavir/ritonavir, indinavir/ritonavir, conivaptan

Dose reduction (patients meeting both criteria would be prescribed with Apixaban 2.5 mb bid)

  • 15 mL/min eGFR < 30 mL/min
  • ESRD patients under 60 kg of bodyweight or age over 80 years old.

Condition Atrial Fibrillation, Atrial Fibrillation (Pediatric), Dysrhythmia, Arrhythmia
Treatment OAC monotherapy, Apixaban monotherapy, Dual therapy with apixaban and clopidogrel, NOAC monotherapy
Clinical Study IdentifierNCT04250116
SponsorYonsei University
Last Modified on23 September 2021


Yes No Not Sure

Inclusion Criteria

over 19 years old
Patient who underwent PCI with DES 12 months to 18 months ago
Non-valvular atrial fibrillation patients requiring long-term anticoagulation

Exclusion Criteria

Over 85 years old
Pregnancy or Potential Pregnancy
Life expectancy within 1 year
Patients who refuse or do not understand the written consent form
Requiring anticoagulation due to history of mechanical valve replacement, mitral stenosis or deep vein thrombosis
Coagulopathy, continuous bleeding, or Hb level below 10 g/dL
Intracerebral hemorrhage within 2 months
Patients with gastrointestinal hemorrhage within three months of registration
Patients diagnosed with a gastrointestinal tumor that requires continuous treatment
Patients treated with 1st generation drug-eluting stents (Cypher, Taxus, or Endeavor Sprint)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note